Literature DB >> 34130596

Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.

Mariana Brütt Pacheco1, Vânia Camilo1, Rui Henrique1,2,3, Carmen Jerónimo1,3.   

Abstract

Epigenome editing consists of fusing a predesigned DNA recognition unit to the catalytic domain of a chromatin modifying enzyme leading to the introduction or removal of an epigenetic mark at a specific locus. These platforms enabled the study of the mechanisms and roles of epigenetic changes in several research domains such as those addressing pathogenesis and progression of cancer. Despite the continued efforts required to overcome some limitations, which include specificity, off-target effects, efficacy, and longevity, these tools have been rapidly progressing and improving.Since prostate cancer is characterized by multiple genetic and epigenetic alterations that affect different signalling pathways, epigenetic editing constitutes a promising strategy to hamper cancer progression. Therefore, by modulating chromatin structure through epigenome editing, its conformation might be better understood and events that drive prostate carcinogenesis might be further unveiled.This review describes the different epigenome engineering tools, their mechanisms concerning gene's expression and regulation, highlighting the challenges and opportunities concerning prostate cancer research.

Entities:  

Keywords:  Prostate cancer; crispr-dCas9; epigenome editing; fusion proteins

Mesh:

Substances:

Year:  2021        PMID: 34130596      PMCID: PMC9067534          DOI: 10.1080/15592294.2021.1939477

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.861


  253 in total

1.  Histone modification: cause or cog?

Authors:  Steven Henikoff; Ali Shilatifard
Journal:  Trends Genet       Date:  2011-07-20       Impact factor: 11.639

Review 2.  The future of epigenetic therapy in solid tumours--lessons from the past.

Authors:  Nilofer Azad; Cynthia A Zahnow; Charles M Rudin; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

Review 3.  Bromodomain-containing proteins in prostate cancer.

Authors:  Alfonso Urbanucci; Ian G Mills
Journal:  Mol Cell Endocrinol       Date:  2017-06-15       Impact factor: 4.102

4.  A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer.

Authors:  Ji-Young Kim; Taraswi Banerjee; Aurimas Vinckevicius; Qianyi Luo; J Brandon Parker; Mairead R Baker; Ishwar Radhakrishnan; Jian-Jun Wei; Grant D Barish; Debabrata Chakravarti
Journal:  Mol Cell       Date:  2014-05-01       Impact factor: 17.970

5.  Novel approach to therapeutic targeting of castration-resistant prostate cancer.

Authors:  Eswar Shankar; Daniel Franco; Omair Iqbal; Victoria El-Hayek; Sanjay Gupta
Journal:  Med Hypotheses       Date:  2020-02-19       Impact factor: 1.538

6.  Breaking the code of DNA binding specificity of TAL-type III effectors.

Authors:  Jens Boch; Heidi Scholze; Sebastian Schornack; Angelika Landgraf; Simone Hahn; Sabine Kay; Thomas Lahaye; Anja Nickstadt; Ulla Bonas
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

7.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

8.  Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators.

Authors:  Lauren R Polstein; Pablo Perez-Pinera; D Dewran Kocak; Christopher M Vockley; Peggy Bledsoe; Lingyun Song; Alexias Safi; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach
Journal:  Genome Res       Date:  2015-05-29       Impact factor: 9.043

Review 9.  Prostate apoptosis response-4 and tumor suppression: it's not just about apoptosis anymore.

Authors:  Anees Rahman Cheratta; Faisal Thayyullathil; Siraj Pallichankandy; Karthikeyan Subburayan; Ameer Alakkal; Sehamuddin Galadari
Journal:  Cell Death Dis       Date:  2021-01-07       Impact factor: 8.469

10.  Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins.

Authors:  Morgan L Maeder; James F Angstman; Marcy E Richardson; Samantha J Linder; Vincent M Cascio; Shengdar Q Tsai; Quan H Ho; Jeffry D Sander; Deepak Reyon; Bradley E Bernstein; Joseph F Costello; Miles F Wilkinson; J Keith Joung
Journal:  Nat Biotechnol       Date:  2013-10-09       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.